Analyst Price Targets — TXG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 13, 2026 1:33 pm | — | Stifel Nicolaus | $70.00 | $72.68 | StreetInsider | 10X Genomics (TXG) PT Raised to $70 at TD Cowen |
| October 12, 2026 12:52 pm | — | Morgan Stanley | $70.00 | $78.95 | TheFly | 10x Genomics price target raised to $70 from $40 at Morgan Stanley |
| October 12, 2026 9:04 am | Kyle Mikson | Canaccord Genuity | $100.00 | $80.65 | TheFly | 10x Genomics price target raised to $100 from $60 at Canaccord |
| October 7, 2026 9:35 am | — | Barclays | $110.00 | $80.66 | TheFly | 10x Genomics price target raised to $110 from $52 at Barclays |
| September 29, 2026 12:51 pm | — | Leerink Partners | $90.00 | $88.43 | TheFly | 10x Genomics price target raised to $90 from $40 at Leerink |
| September 28, 2026 11:47 am | — | Argus Research | $110.00 | $85.71 | TheFly | 10x Genomics initiated with a Buy at Argus |
| September 28, 2026 10:46 am | — | Piper Sandler | $80.00 | $85.71 | TheFly | 10x Genomics price target raised to $80 from $47 at Piper Sandler |
| September 9, 2026 11:31 am | Doug Schenkel | UBS | $68.00 | $65.60 | TheFly | 10x Genomics assumed with a Neutral at UBS |
| September 1, 2026 6:13 am | Dan Leonard | RBC Capital | $70.00 | $62.45 | StreetInsider | RBC Capital Starts 10X Genomics (TXG) at Sector Perform |
| August 12, 2026 1:09 pm | Mason Carrico | Stephens | $65.00 | $58.34 | TheFly | 10x Genomics price target raised to $65 from $50 at Stephens |
Latest News for TXG
PLEASANTON, Calif., Oct. 27, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced today that members of its management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in London on Tuesday, November 17, at 4:30 p.m.
On October 16, 2026, 10x Genomics Inc (TXG) shares fell 3.5%, bringing the current price to $69.86. The stock has experienced significant price fluctuations, wi
PLEASANTON, Calif., Oct. 13, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the third quarter ended September 30, 2026 after market close on Thursday, November 5, 2026.
Forget the "Magnificent Seven" in favor of the "Tremendous Three"?
TXG teams up with Fred Hutchinson Cancer Center to advance precision oncology through single-cell and spatial technologies targeting two cancer types.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TXG.
U.S. House Trading
No House trades found for TXG.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.